Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06146114
Status:
RECRUITING
Last Update Posted:
2023-11-24
First Post:
2023-11-17
Brief Title:
Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
Sponsor:
Qilu Hospital of Shandong University
Organization:
Qilu Hospital of Shandong University
Study Overview
Official Title:
Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single center non-interference retrospective registration study HER2 testing and disease information collection were conducted on patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023 Statistical analysis was conducted on the collected information to analyze the expression of HER2 in Chinese prostate patients and the correlation between HER2 and disease type
Detailed Description:
1 To explore the expression of HER2 protein in prostate cancer patients admitted to Qilu Hospital of Shandong University especially the expression rate of HER2 protein under different pathological characteristics age TNM grade primary and metastasis and to explore the correlation between HER2 protein expression level efficacy and prognosis based on patient clinical information
2 1 Main Purpose
Analyze the expression of HER2 in prostate cancer patients admitted to Qilu Hospital of Shandong University
2 Secondary purpose
The expression of HER2 protein under different clinical and pathological characteristics age TNM grade primary and metastasis
3Main indicators
The expression of HER2 in prostate cancer patients
Secondary indicators
1 The correlation between HER2 expression IHC0123 and disease characteristics in locally advanced or metastatic prostate cancer patients
2 The distribution of HER2 expression in different ages different parts different degrees of differentiation and different TNM stages Evaluate the expression of primary and metastatic lesions in patients with metastasis
2 1 Main Purpose
Analyze the expression of HER2 in prostate cancer patients admitted to Qilu Hospital of Shandong University
2 Secondary purpose
The expression of HER2 protein under different clinical and pathological characteristics age TNM grade primary and metastasis
3Main indicators
The expression of HER2 in prostate cancer patients
Secondary indicators
1 The correlation between HER2 expression IHC0123 and disease characteristics in locally advanced or metastatic prostate cancer patients
2 The distribution of HER2 expression in different ages different parts different degrees of differentiation and different TNM stages Evaluate the expression of primary and metastatic lesions in patients with metastasis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None